References

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

10.1056/nejmoa043330 · 2005 · External reference

Protein degradation and protection against misfolded or damaged proteins

10.1038/nature02263 · 2003 · External reference

The ubiquitin-proteasome pathway in cancer

10.1038/bjc.1998.71 · 1998 · External reference

The regulation of proteasome degradation by multiubiquitin chain binding proteins

10.1016/j.febslet.2005.03.042 · 2005 · External reference

The proteasome in cancer biology and treatment

10.1667/0033-7587(2001)156[0447:tpicba]2.0.co;2 · 2001 · External reference

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy

10.1634/theoncologist.8-6-508 · 2003 · External reference

Bortezomib for the treatment of mantle cell lymphoma

10.1158/1078-0432.ccr-07-0871 · 2007 · External reference

Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells

2008 · External reference

Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts

2008 · External reference

Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies

10.1016/j.ijrobp.2008.08.050 · 2008 · External reference

Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora

10.1002/anie.200390115 · 2003 · External reference

Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor

10.1021/jm048995+ · 2005 · External reference

The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia

10.1158/1535-7163.mct-06-0066 · 2006 · External reference

A novel proteasome inhibitor NPI-0052 as an anticancer therapy

10.1038/sj.bjc.6603406 · 2006 · External reference

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

10.1016/s1470-2045(09)70025-7 · 2009 · External reference

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

10.1038/nature07385 · 2008 · External reference

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib

10.1016/j.ccr.2005.10.013 · 2005 · External reference

The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism

10.1186/1471-2407-5-76 · 2005 · External reference

The proteasome inhibitor MG-132 protects hypoxic SiHa cervical carcinomacells after cyclic hypoxia/reoxygenation from ionizing radiation

10.1593/neo.06634 · 2006 · External reference

The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells

2002 · External reference

Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition

10.1016/s0360-3016(00)00516-2 · 2000 · External reference

Molecular pathways that modify tumor radiation response

10.1097/00000421-200110000-00013 · 2001 · External reference

Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours

10.1016/j.ejca.2008.05.022 · 2008 · External reference

Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor

10.1038/sj.bjc.6605043 · 2009 · External reference

A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy

10.1007/s10637-008-9154-z · 2009 · External reference

Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM)

10.1038/sj.onc.1208225 · 2005 · External reference

Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines

10.1016/j.ijrobp.2007.07.2366 · 2007 · External reference

PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells

10.1016/j.stem.2009.01.007 · 2009 · External reference

Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation

10.1158/1535-7163.mct-07-2198 · 2008 · External reference

Combination of PTEN and gamma-ionizing radiation enhances cell death and G(2)/M arrest through regulation of AKT activity and p21 induction in non-small-cell lung cancer cells

10.1016/j.ijrobp.2007.11.069 · 2008 · External reference

Survival of human glioma cells treated with various combination of temozolomide and x-rays

10.1016/s0360-3016(99)00539-8 · 2000 · External reference

Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer

1999 · External reference

Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line

10.1007/s00280-004-0811-4 · 2004 · External reference

DNA repair and cancer stem-like cells—potential partners in glioma drug resistance?

10.1016/j.ctrv.2008.03.125 · 2008 · External reference

The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells

1998 · External reference

In-vivo imaging, tracking, and targeting of cancer stem cells

10.1093/jnci/djn509 · 2009 · External reference